Article Text

Download PDFPDF
Orchard Sports Injury and Illness Classification System (OSIICS) version 14 and Italian translation
  1. John Orchard1,
  2. Federico Genovesi2
  1. 1School of Public Health, The University of Sydney, Sydney, New South Wales, Australia
  2. 2Manchester City Football Club, Manchester, UK
  1. Correspondence to Dr John Orchard, School of Public Health, The University of Sydney, Sydney, NSW 2006, Australia; john.orchard{at}sydney.edu.au

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

The Orchard Sports Injury and Illness Classification System (OSIICS) was released in version 13 as an upgrade to the Orchard Sports Injury Classification System in early 2020,1 after being conceived at an IOC consensus meeting in Lausanne in October 2019,2 alongside a new version of the Sport Medicine Diagnostic Coding System (SMDCS). This was less than 3 years ago (a short time) but seemingly eons back in the prepandemic days when international flying was like catching a bus. As with all classification systems, the OSIICS requires reassessment and updating, in this case to OSIICS version 14.0 (figure 1).

Figure 1

Orchard Sports Injury and Illness Classification System (OSIICS) version 14 logo.

Coding for COVID-19

Minor changes to OSIICS version 13 (versions 13.1–13.5) have been made over 2020 and 2021. Just prior to releasing version 13.1, an email was sent to other members of the IOC consensus team asking ‘Do you think this new viral illness, COVID-19, warrants a specific code?’ At that early stage, some …

View Full Text

Footnotes

  • Twitter @DrJohnOrchard

  • Contributors FG wrote the Italian translation and JO wrote the updates to version 14 and the majority of the text.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.